Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

81. Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis (Abstract)

Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis To assess the effects of breathing exercises on postoperative pulmonary complications (PPCs), pulmonary function, 6-min walk distance (6MWD) and the length of hospital stay (LOS) in lung cancer patients undergoing lung surgery.Lung cancer patients undergoing lung resection have poor pulmonary function and multiple PPCs. Breathing exercises may improve (...) exercises could improve lung function, decrease the incidence of PPCs and LOS in a sample of lung cancer patients undergoing pulmonary surgery.The analysis suggests that breathing exercises should be considered as a respiratory rehabilitation programme for lung cancer patients undergoing lung surgery in clinical practice.© 2018 John Wiley & Sons Ltd.

2019 EvidenceUpdates

82. Meta-analysis of intentional segmentectomy versus lobectomy for pathologically stage T1N0 non-small cell lung cancer

Meta-analysis of intentional segmentectomy versus lobectomy for pathologically stage T1N0 non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

83. Dose-response analysis of dietary vitamin A and beta-carotene intake with the risk of lung cancer

Dose-response analysis of dietary vitamin A and beta-carotene intake with the risk of lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2019 PROSPERO

84. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) versus mediastinoscopy for mediastinal lymph node staging of lung cancer: a systematic review of economic evaluation studies

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) versus mediastinoscopy for mediastinal lymph node staging of lung cancer: a systematic review of economic evaluation studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

85. Efficacy, effectiveness and safety of checkpoint inhibitors for non small cell lung cancer: systematic review and meta-analysis

Efficacy, effectiveness and safety of checkpoint inhibitors for non small cell lung cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

86. Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of patients with lung cancer: a meta-analysis

Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of patients with lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

87. Association between PD-L1 expression level and efficacy of PD1 or PD-L1 immune checkpoint inhibitors in the treatment of lung cancer: a systematic review and meta-analysis

Association between PD-L1 expression level and efficacy of PD1 or PD-L1 immune checkpoint inhibitors in the treatment of lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

88. A systematic review of somatic tumour gene panel testing for non-small-cell lung cancer (NSCLC)

A systematic review of somatic tumour gene panel testing for non-small-cell lung cancer (NSCLC) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2019 PROSPERO

89. Significance of co-genetic driver mutations in EGFR mutated non small-cell lung cancer in outcomes to treatment with tyrosine kinase inhibitors

Significance of co-genetic driver mutations in EGFR mutated non small-cell lung cancer in outcomes to treatment with tyrosine kinase inhibitors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

90. Preoperative nutrition for patients with non-small cell lung cancer: a systematic review

Preoperative nutrition for patients with non-small cell lung cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

91. Predictors of adherence to lung cancer screening programs: a systematic review

Predictors of adherence to lung cancer screening programs: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2019 PROSPERO

92. The efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with central nervous system metastasis: a meta-analysis of randomized controlled trials

The efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with central nervous system metastasis: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

93. The effect of herbal medicines for treating radiation pneumonitis in lung cancer patients: protocol for a systematic review

The effect of herbal medicines for treating radiation pneumonitis in lung cancer patients: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

94. The comparative efficacy and safety of antiPD-1/PD-L1 antibody therapies for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer: a systematic review and network meta-analysis

The comparative efficacy and safety of antiPD-1/PD-L1 antibody therapies for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2019 PROSPERO

95. Therapeutic vaccines for advanced non-small cell lung cancer [Cochrane protocol]

Therapeutic vaccines for advanced non-small cell lung cancer [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

96. Efficacy and safety of six third-generation chemotherapeutic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, pemetrexed and nab-paclitaxel) combined with platinum in the treatment of advanced non-small cell lung cancer: a network meta-analysis

Efficacy and safety of six third-generation chemotherapeutic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, pemetrexed and nab-paclitaxel) combined with platinum in the treatment of advanced non-small cell lung cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

97. Efficacy of therapeutics for advanced EGFR mutation positive non-small cell lung cancer: a real-world, Bayesian network secondary study of multivariable-survival analyses using per-protocol principles

Efficacy of therapeutics for advanced EGFR mutation positive non-small cell lung cancer: a real-world, Bayesian network secondary study of multivariable-survival analyses using per-protocol principles Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

98. The prognostic value of advanced lung cancer inflammation index (ALI) in lung cancer: a systematic review and meta-analysis

The prognostic value of advanced lung cancer inflammation index (ALI) in lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

99. The physical activity paradox in lung cancer: a systematic review and meta-analyses

The physical activity paradox in lung cancer: a systematic review and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

100. The association of MAGE-A gene expression with clinicopathological characteristics and prognosis in resected non-small cell lung cancer: a meta-analysis

The association of MAGE-A gene expression with clinicopathological characteristics and prognosis in resected non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO